| Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
|---|---|---|---|---|---|---|
| 2016 | 151P: Outcomes of research biopsies in clinical trials of EGFR mutation-positive NSCLC patients pretreated with EGFR-TKIs | Liao B.-C.; Bai Y.-Y.; Lin C.-C.; Lin S.-Y.; Lee Y.-F.; Ho C.-C.; Shih J.-Y.; Chang Y.-C.; CHONG-JEN YU ; Yang J. | Journal of Thoracic Oncology | |||
| 2016 | 205P: Visualizing ZO-1-mediated coupled migration between cancer and stromal cells in lung cancer metastasis via a 5-dimensional cell imaging system | Lu H.-H.; Chen B.-C.; Chen H.-W.; Ho C.-C.; CHONG-JEN YU | Journal of Thoracic Oncology | |||
| 2008 | A 50-year-old man with bilateral pulmonary tumours | Lin P.-Y.; Chen J.-S.; Ku S.-C.; Wu M.-Z.; CHONG-JEN YU ; Yang P.-C. | Thorax | |||
| 2010 | The 5p15.33 locus is associated with risk of lung adenocarcinoma in never-smoking females in Asia | Hsiung C.A.; Lan Q.; Hong Y.C.; Chen C.-J.; Dean Hosgood H.; Chang I.-S.; Chatterjee N.; Brennan P.; Wu C.; Zheng W.; Chang G.-C.; Wu T.; Park J.Y.; Hsiao C.-F.; Kim Y.H.; Shen H.; Seow A.; Yeager M.; Tsai Y.-H.; Kim Y.T.; Chow W.-H.; Guo H.; Wang W.-C.; Sung S.W.; Hu Z.; Chen K.-Y.; Kim J.H.; Chen Y.; Huang L.; Lee K.-M.; Lo Y.-L.; Gao Y.-T.; Kim J.H.; Liu L.; Huang M.-S.; Jung T.H.; Jin G.; Caporaso N.; Yu D.; Kim C.H.; Su W.-C.; Shu X.-O.; Xu P.; Kim I.-S.; Chen Y.-M.; Ma H.; Shen M.; Cha S.I.; Tan W.; Chang C.-H.; Sung J.S.; Zhang M.; Yang T.-Y.; Park K.H.; Yuenger J.; Wang C.-L.; Ryu J.-S.; Xiang Y.; Deng Q.; Hutchinson A.; Kim J.S.; Cai Q.; Landi M.T.; CHONG-JEN YU ; Park J.-Y.; Tucker M.; Hung J.-Y.; Lin C.-C.; Perng R.-P.; Boffetta P.; Chen C.-Y.; Chen K.-C.; Yang S.-Y.; Hu C.-Y.; Chang C.-K.; Fraumeni Jr. J.F.; Chanock S.; Yang P.-C.; Rothman N.; Lin D. | PLoS Genetics | |||
| 2002 | Aberrant p53 expression correlates with expression of vascular endothelial growth factor mRNA and interleukin-8 mRNA and neoangiogenesis in non-small-cell lung cancer | Yuan A.; CHONG-JEN YU ; Luh K.-T.; Kuo S.-H.; Lee Y.-C.; Yang P.-C. | Journal of Clinical Oncology | |||
| 2017 | Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib | Ho C.-C.; Liao W.-Y.; Lin C.-A.; Shih J.-Y.; CHONG-JEN YU ; Chih-Hsin Yang J. | Journal of Thoracic Oncology | |||
| 2005 | Acquired gefitinib-resistant mutation of EGFR in a chemonaive lung adenocarcinoma harboring gefitinib-sensitive mutation L858R | Gow C.-H.; Shih J.-Y.; Chang Y.-L.; CHONG-JEN YU | PLoS Medicine | |||
| 2016 | Acquisition of Mycobacterium abscessus among ventilator-dependent patients in Taiwan chronic respiratory care facilities | Lee M.-R.; Tsai C.-J.; Hu J.-Y.; Lee S.-W.; Ko J.-C.; Wang H.-C.; CHONG-JEN YU ; Lee L.-N.; Hsueh P.-R. | Future Microbiology | |||
| 2014 | Acute kidney injury due to anti-tuberculosis drugs: A five-year experience in an aging population | Chang C.-H.; Chen Y.-F.; Wu V.-C.; Shu C.-C.; Lee C.-H.; Wang J.-Y.; Lee L.-N.; CHONG-JEN YU | BMC Infectious Diseases | |||
| 2001 | Acute respiratory distress syndrome in a woman with heroin and methamphetamine misuse | Yeh P.-S.; Yuan A.; CHONG-JEN YU ; Kuo S.-H.; Luh K.-T.; Yang P.-C. | Journal of the Formosan Medical Association | |||
| 2010 | Adding moxifloxacin is associated with a shorter time to culture conversion in pulmonary tuberculosis | Wang J.-Y.; Wang J.-T.; Tsai T.-H.; Hsu C.-L.; CHONG-JEN YU ; Hsueh P.-R.; Lee L.-N.; Yang P.-C. | International Journal of Tuberculosis and Lung Disease | |||
| 2022 | The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70 | Boutry C.; Hastie A.; Diez-Domingo J.; Tinoco J.C.; CHONG-JEN YU ; Andrews C.; Beytout J.; Caso C.; Cheng H.-S.; Cheong H.J.; Choo E.J.; Curiac D.; Di Paolo E.; Dionne M.; Eckermann T.; Esen M.; Ferguson M.; Ghesquiere W.; Hwang S.-J.; Avelino-Silva T.J.; Kosina P.; Liu C.-S.; Markkula J.; Moeckesch B.; Murta de Oliveira C.; Park D.W.; Pauksens K.; Pirrotta P.; Plassmann G.; Pretswell C.; Rombo L.; Salaun B.; Sanmartin Berglund J.; Schenkenberger I.; Schwarz T.; Shi M.; Ukkonen B.; Zahaf T.; Zerbini C.; Schuind A.; Cunningham A.L.; Zoster-049 Study Group | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | |||
| 2021 | The adjuvanted recombinant zoster vaccine is efficacious and safe in Asian adults ? 50 years of age: a sub-cohort analysis of the ZOE-50 and ZOE-70 randomized trials | Kim J.H.; Diaz-Decaro J.; Jiang N.; Hwang S.-J.; Choo E.J.; Co M.; Hastie A.; Hui D.S.C.; Irimajiri J.; Lee J.; Leung E.M.-F.; Tang H.; Tsuru T.; Watson P.; Wu Z.; CHONG-JEN YU ; Yuan Y.; Zahaf T.; Cunningham A.L.; Schuind A.; on behalf of the ZOE-50/70 Asian study group | Human Vaccines and Immunotherapeutics | |||
| 2011 | Admissions to intensive care unit of HIV-infected patients in the era of highly active antiretroviral therapy: Etiology and prognostic factors | Chiang H.-H.; Hung C.-C.; Lee C.-M.; Chen H.-Y.; Chen M.-Y.; Sheng W.-H.; Hsieh S.-M.; Sun H.-Y.; Ho C.-C.; CHONG-JEN YU | Critical Care | |||
| 2008 | Adrenal insufficiency in prolonged critical illness | Wu J.-Y.; Hsu S.-C.; Ku S.-C.; Ho C.-C.; CHONG-JEN YU ; Yang P.-C. | Critical Care | |||
| 2012 | Advanced non-small cell lung cancer in patients aged 45 years or younger: Outcomes and prognostic factors | Hsu C.-L.; Chen K.-Y.; Shih J.-Y.; Ho C.-C.; Yang C.-H.; CHONG-JEN YU ; Yang P.-C. | BMC Cancer | |||
| 2015 | Advanced non-small cell lung cancer in the elderly: The impact of age and comorbidities on treatment modalities and patient prognosis | Hsu C.-L.; Chen J.-H.; Chen K.-Y.; Shih J.-Y.; Yang J.C.H.; CHONG-JEN YU ; Yang P.-C. | Journal of Geriatric Oncology | |||
| 2019 | Advanced physical examination training course improves medical students' confidence in physical examination | Tseng F.-Y.; Chang Y.-T.; CHONG-JEN YU ; Chang S.-C. | Journal of the Formosan Medical Association | |||
| 2012 | Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): A phase 2 trial | Yang J.C.H.; Shih J.-Y.; Su W.-C.; Hsia T.-C.; Tsai C.-M.; Ou S.H.I.; CHONG-JEN YU ; Chang G.-C.; Ho C.-L.; Sequist L.V.; Dudek A.Z.; Shahidi M.; Cong X.J.; Lorence R.M.; Yang P.-C.; Miller V.A. | The Lancet Oncology | |||
| 2015 | Afatinib induces apoptosis in NSCLC without EGFR mutation through Elk-1-mediated suppression of CIP2A | Chao T.-T.; Wang C.-Y.; Chen Y.-L.; Lai C.-C.; Chang F.-Y.; Tsai Y.-T.; Chao C.-H.H.; Shiau C.-W.; Huang Y.-C.T.; CHONG-JEN YU ; Chen K.-F. | Oncotarget |
